在牛皮中准JAK/STAT途径的治疗潜力:关注TYK2抑制
Martina Dragotto1, Martina D'Onghia1, Emanuele Trovato1
1Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy.
Journal of clinical medicine
|June 19, 2024
概括
新的口服TYK2抑制剂在治疗牛皮方面表现有前途,通过向特定的炎症途径,为广泛的JAK抑制剂提供了潜在的更安全的替代方案. 这些药物可以解决管理这种慢性皮肤疾病的未满足需求.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛皮是一种慢性炎症性皮肤疾病,严重影响生活质量.
- 现有的牛皮治疗方法有局限性,这促使人们寻找新的治疗方法.
- JAK/STAT通路涉及到牛皮病原体,提供了一个治疗点.
研究的目的:
- 审查JAK抑制剂治疗牛皮的理由,疗效和安全性.
- 专注于口服TYK2抑制剂作为一个有前途的治疗策略.
- 提供关于用于治疗牛皮的新型TYK2向剂的最新信息.
主要方法:
- 在牛皮中对JAK/STAT通路抑制剂的当前文献的综述.
- 对口服JAK抑制剂的临床试验数据的分析,包括安全问题.
- 选择性TYK2抑制剂 (deucravacitinib,brepocitinib,PF-06826647) 的检查及其机制.
主要成果:
- 抑制JAK/STAT可为复杂的牛皮病原体提供治疗优势.
- 口服JAK抑制剂引发了安全问题 (感染,VTE,恶性瘤).
- 选择性TYK2抑制剂显示出与泛JAK抑制剂相比,由于向细胞因子阻断 (IL-12,IL-23) 的原因,可能改善安全性.
结论:
- 选择性TYK2抑制是牛皮的有希望的治疗途径.
- 口服TYK2抑制剂可能比更广泛的JAK抑制剂提供更高的安全性.
- 对TYK2向剂的进一步研究是有效的牛皮管理的必要条件.
相关概念视频
01:20The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
01:24T Cell Types and Functions
999
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
999
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:22Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
01:16TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K